The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

New SLAMF7-targeted CAR T-cell therapy

Sep 29, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Hermann Einsele, University Hospital of Würzburg, Würzburg, DE, about chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

New SLAMF7-targeted CAR T-cell therapy

Hermann Einsele details a case where a patient being treated with anti-B-cell maturation antigen (BCMA) CAR T-cell therapy underwent reversible loss of BCMA expression. In response to this, he describes the creation of CAR T cells against SLAMF7 and discusses in vivo results and the CARAMBA project.